# Sprout Group

> Sprout Group is a VC fund in New York backing Health Care and Biotechnology. See 109 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 109
- Last investment: Mar 2016
- Lead investor: 28%
- Last fund: Jan 2004
- Last updated: Aug 2026

Sprout Group is a VC fund in New York focused on Health Care and Biotechnology. Sprout Group is one of the oldest and largest institutional venture capital firms focused on emerging companies. Since its founding in 1969, Sprout Group has financed more than 350 companies and has raised nearly $3.0 billion in committed capital from leading institutional investors and individuals. In November 2000, Sprout Group closed Sprout IX,a fund totaling $1.1 billion.

## Contacts

5 contacts available for Sprout Group. Shizune tracks 4 team members at Sprout Group. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/the-sprout-group?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series B | $8M–$70M |
| Series C | $8.5M–$80M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 22 | 20% |
| Biotechnology | 15 | 14% |
| Medical | 14 | 13% |
| Software | 12 | 11% |
| Internet | 10 | 9% |

81 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 26 | 24% |
| Series C | 20 | 18% |
| Funding Round | 18 | 17% |
| Series A | 13 | 12% |
| Series D | 13 | 12% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 61 | 56% |
| Canada | 2 | 2% |
| India | 1 | 1% |
| United Arab Emirates | 1 | 1% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Craig Parker | Director | 0 | https://shizune.co/investors/profile/craig-parker |
| Craig Parker | Director | 1 | https://shizune.co/investors/profile/craig-parker-aca2 |
| Janet Hickey | Co-Managing Partner | 2 | https://shizune.co/investors/profile/janet-hickey |
| Steve Rattner | Managing Director | 0 | https://shizune.co/investors/profile/steve-rattner |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CallFixie | CallFixie is a new, FREE online service that connects tradies and customers Australia wide. Unlike Their competitors, They have no sign up or ongoing subscription fees.As a customer, it is FREE to post your job and, as a Fixie, it is FREE to post unlimited quotes. Their easy-to-use website and mobile apps take the hassle out of finding aqualified tradie (or, as They like to call them, “Fixies”) to get your job SORTED.CallFixie gives you access to thousands of Fixies across Australia, covering all trades and services. So, no matter where you are or how big or small your job is, CallFixie will get it SORTED. | $2M | Seed | Mar 31, 2016 |  |
| Relypsa | Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa isdedicated to discover additional product candidates through use of its proprietary polymer platform. | $80M | Series C | Aug 14, 2012 |  |
| Relypsa | Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa isdedicated to discover additional product candidates through use of its proprietary polymer platform. | $62.4M | Private Equity | Jul 01, 2012 |  |
| Relypsa | Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa isdedicated to discover additional product candidates through use of its proprietary polymer platform. | $70.1M | Series B | Aug 08, 2011 |  |
| CyOptics | CyOptics, Inc. designs, develops, and markets Indium Phosphide (InP) optical chips and components for integration into access, metro, and long-haul communications systems. Its products include planar lightwave circuits (PLCs) for optical networks in telecommunications and defense applications. The company's products also include opticalcomponents, including transmitters, receivers, and modulators for transmission; and optical source and laser detector chips as technology enablers for transmit optical sub-assembly/receive optical sub-assembly, component, and module manufacturers. In addition, it provides contract design, foundry, and packaging services; and design and manufacturing services, such as radio frequency and optical design, wafer/chip fabrication, and automated assembly and test for telecom and non-telecom applications. The company's customers include system original equipment manufacturers and sub-system manufacturers in the communications market. CyOptics, Inc. was founded in 1999 and is based in Breinigsville, Pennsylvania. The company has InP design and fabrication operations in Lehigh Valley, Pennsylvania; silicon PLC fab operations in South Plainfield, New Jersey; and planar automated packaging and testing operations in Matamoros, Mexico. | $50M | Private Equity | Jan 26, 2011 |  |
| Relypsa | Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa isdedicated to discover additional product candidates through use of its proprietary polymer platform. | $70M | Series B | Sep 13, 2010 |  |
| Aureon Laboratories | Aureon Laboratories is a life sciences company dedicated to enabling the advancement of predictive and personalized cancer treatment. Aureon provides objective, actionable information allowing patients and physicians to make more-informed treatment decisions through its prostate diagnostic tools. | $7M | Series D | Apr 14, 2010 |  |
| TradeBeam | TradeBeam provided trade management software and services company streamlining global trading processes for enterprises and their partners. | $7M |  | Sep 21, 2009 |  |
| Calix | Calix cloud and software platforms enable service providers of all types and sizes to innovate and transform. Our customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates morevalue for their businesses and communities. This is the Calix mission; to enable communications service providers of all sizes to simplify, excite and grow. | $50M |  | Aug 31, 2009 |  |
| CareDx | CareDx is a molecular diagnostics company based in Brisbane, CA, USA. XDx applies modern genomics technologies to the development of molecular diagnostic assays that translate a patient's immune status into clinically actionable information. XDx has one marketed product, AlloMap Molecular Expression Testing, and other products underdevelopment. The proprietary molecular expression technology used by XDx to develop AlloMap testing for heart transplant patient management may be applicable to the post-transplant management of recipients of other organs. The application of gene expression testing to other diseases that involve the activity of the immune system, such as autoimmune and chronic inflammatory diseases, is also being explored. | $14.4M | Series G | Aug 05, 2009 |  |

10 of 109 investments shown.

## Co-investors
- [Three Arch Partners](https://shizune.co/investors/profile/three-arch-partners) — VC Fund, 9 deals together
- [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 7 deals together
- [Delphi Ventures](https://shizune.co/investors/profile/delphi-ventures) — VC Fund, 7 deals together
- [Jerusalem Venture Partners (JVP)](https://shizune.co/investors/profile/jerusalem-venture-partners) — VC Fund, 7 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 7 deals together
- [Norwest](https://shizune.co/investors/profile/norwest-venture-partners) — VC Fund, 6 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Everywhere Ventures](https://shizune.co/investors/profile/everywhere-ventures) — VC Fund
- [Andreessen Horowitz](https://shizune.co/investors/profile/andreessen-horowitz) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Titan Capital](https://shizune.co/investors/profile/titan-capital) — VC Fund
- [Inflection Point Ventures](https://shizune.co/investors/profile/inflection-point-ventures-d275) — VC Fund
- [Blume Ventures](https://shizune.co/investors/profile/blume-ventures) — VC Fund

## Featured in investor lists
- [Infrastructure VC Funds in India](https://shizune.co/investors/infrastructure-vc-funds-india)
- [Infrastructure Investors in India](https://shizune.co/investors/infrastructure-investors-india)

## FAQ

### What does Sprout Group invest in?

Sprout Group invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series C stage. Most of the 109 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Sprout Group's check size?

Sprout Group typically joins rounds of $8M–$70M at Series B and $8.5M–$80M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sprout Group participates in.

### How do I contact Sprout Group?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Sprout Group?

The team at Sprout Group includes Craig Parker (Director), Craig Parker (Director) and Janet Hickey (Co-Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co